CN1326535C - Medicine for treating bong arthritis and its preparing method - Google Patents
Medicine for treating bong arthritis and its preparing method Download PDFInfo
- Publication number
- CN1326535C CN1326535C CNB2005100955653A CN200510095565A CN1326535C CN 1326535 C CN1326535 C CN 1326535C CN B2005100955653 A CNB2005100955653 A CN B2005100955653A CN 200510095565 A CN200510095565 A CN 200510095565A CN 1326535 C CN1326535 C CN 1326535C
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- medicine
- radix angelicae
- osteoarthritis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Abstract
The present invention relates to a medicament for treating osteoarthritis and a preparation method thereof, which is characterized in that the medicament is prepared from drynaria, cyathula root, pubescent angelica, mistletoe, pilose asiabell root, angelica, honeycomb, spatholobus stem and clematis root. The medicament can be prepared into any common oral preparation form, has the efficacy of reinforcing the kidney, invigorating the spleen, promoting blood circulation and dispelling cold, and is used for treating asthenia of both the spleen and the kidney, and cold wetness and stasis blockage for osteoarthritis. Pharmacodynamic study proves that the medicament has the functions of analgesia, inflammation resistance, blood circulation promotion, blood stasis removal, and treatment and prevention of osteoarthritis.
Description
Technical field:
The present invention relates to a kind of medicine for the treatment of osteoarthritis and preparation method thereof, belong to the field of Chinese medicines.
Background technology:
Osteoarthritis (Osteoarthritis) is called for short OA, claim degenerative osteoarthritis, hyperosteogeny again, being one is core with the articular cartilage degenerative change, involve sclerotin and comprise synovial membrane, joint capsule and other structures of joint comprehensive, at many levels, chronic inflammatory disease in various degree, be a kind of aseptic, chronic, carry out the assault sexually joint, the disease in the joint of particularly bearing a heavy burden.OA is the common disease of middle-aged and elderly people, also is the most common joint disease.The main clinical characters of OA is, lesion growth just is difficult to reverse after the symptom to occurring, the treatment difficulty, and pain, swelling, deformity, function limitation are the classical symptoms of OA.The medicine of treatment osteoarthritis has at present:
1, the medicine of controlling symptoms: analgesics: acetyl aminophenol and NSAID (non-steroidal anti-inflammatory drug) (NSAIDS), as aspirin, salicylic acid, Phenylbutazone, indomethacin and naproxen etc., symptom such as alleviating pain effectively, temporarily improve function of joint, but can not block the progress of OA, can not improve the pathological state of tissue such as articular cartilage; These medicines may cause some untoward reaction in addition, thereby generally do not advise the long-term use that continues.
2, improve the medicine and the Chondroprotective agents of the state of an illness: this type of medicine has the active function that reduces matrix metalloproteinase, collagenase etc., both can antiinflammatory, pain relieving, can protect articular cartilage again, and the effect that delays the osteoarthritis development is arranged.General onset is slower, and main medicine comprises glucosamine sulfate, glucosaminoglycan, S-ademetionine and doxycycline etc.This type of medicine can't also have a lot of aspects to need research as essential drugs clinically.
3, injection treatment: comprise pain spot injection and intraarticular injection.Clinical proof intra-articular injection hyaluronate sodium is preferable for the serious and lopsided unconspicuous early stage patient curative effect of pain, but for the not good enough and late result of a large amount of sepages and significantly fat patient's curative effect being arranged uncertainly.Domestic existing goods such as sodium hyaluronate injection, import preparation such as Xin Wei can wait.By retrieval, though OA is clinically commonly encountered diseases, frequently-occurring disease, still lack the Chinese medicine preparation of real effectively treatment osteoarthritis in the market.
Summary of the invention:
Technical problem to be solved by this invention is to avoid above-mentioned existing in prior technology weak point, provides a kind of and can control the osteoarthritis symptom rapidly, improves function of joint, toxic and side effects is little, can more effectively treat the medicine of osteoarthritis.
The present invention provides the preparation method of this medicine simultaneously.
The present invention treats the medicine of osteoarthritis, is characterized in being made by following bulk drugs:
Rhizoma Drynariae 6-12 part, Radix Cyathulae 5-9 part, Radix Angelicae Pubescentis 5-9 part, Herba Taxilli 8-15 part, Radix Codonopsis 10-20 part, Radix Angelicae Sinensis 5-10 part, Nidus Vespae 2.5-5 part, Caulis Spatholobi 6-12 part, Radix Clematidis 4-8 part.
The characteristics of process for preparing medicine of the present invention are to be undertaken by following process:
By proportioning get Rhizoma Drynariae, Radix Angelicae Pubescentis adds alcohol reflux, extracting solution filters, the alcohol extraction filtrate for later use;
Get Radix Cyathulae, Herba Taxilli, Radix Codonopsis, Radix Angelicae Sinensis, Nidus Vespae, Caulis Spatholobi, Radix Clematidis by proportioning, decoct with water, decocting liquid filters, and filtrate simmer down to clear paste, clear paste are put and added ethanol after cold and make and contain the alcohol amount and reach 60-70%, stir evenly, and leave standstill, and filter; Filtrate and above-mentioned alcohol extraction filtrate merge, and reclaim ethanol, are concentrated into thick paste, add adjuvant, and drying is pulverized, and mixing is granulated, oven dry, and granulate is promptly.
In addition, medicine of the present invention also can adopt the conventional method of Chinese medicine preparation to be prepared into the oral preparations of any routine.
In described compatibility of drugs:
Rhizoma Drynariae: hardship, temperature.Return kidney, Liver Channel.The kidney invigorating bone strengthening continues and hinders pain relieving.Be used for lumbago due to renal deficiency, Hiccough and deaf, odontoseisis, falling winks frustrates, and the muscles and bones folding is hindered.
Radix Cyathulae: sweet, little hardship, flat.Return liver, kidney channel.Eliminating blood stasis and inducing menstruation, easing joint movement, inducing diuresis for treating stranguria syndrome.Be used for arthralgia, flaccidity of the lower limbs clonic spasm of the muscle, hematuria stranguria with blood, injury from falling down.
Radix Angelicae Pubescentis: hot, bitter, tepor.Return kidney, urinary bladder channel.Expelling wind and removing dampness, numbness relieving and pain relieving.Be used for anemofrigid-damp arthralgia, lumbocrural pain, few cloudy volt wind headache.
Herba Taxilli: bitter, sweet, flat.Return liver, kidney channel.Invigorating the liver and kidney, bone and muscle strengthening, wind-damp dispelling, antiabortive unit.Be used for rheumatic arthralgia, soreness of the waist and knees, muscles and bones is unable, and the metrorrhagia warp is many, blood leaking in gestation, frequent fetal movement; Hypertension.
Radix Codonopsis: sweet, flat.Return spleen, lung meridian.Invigorating the spleen and replenishing QI, the spleen invigorating lung benefiting.Be used for deficiency of the spleen and lung, the cardiopalmus of breathing hard, anorexia and loose stool, the dyspnea due to deficiency cough, interior-heat is quenched one's thirst.
Radix Angelicae Sinensis: sweet, hot, temperature.Return liver, the heart, spleen channel.Enrich blood and invigorate blood circulation, menstruction regulating and pain relieving, loosening bowel to relieve constipation.Be used for blood deficiency and yellow complexion, dizzy cardiopalmus, menoxenia, amenorrhea dysmenorrhea, asthenia cold abdominalgia, dryness of the intestine constipation, rheumatic arthralgia, injury from falling down, ulcer sores.
Nidus Vespae: sweet, flat.Return the stomach warp.Dispel the wind counteracting toxic substances, parasite killing, pain relieving.Be used for toothache due to dental caries, sore swollen toxin, acute mastitis, scrofula, skin stubborn dermatitis, fungal infection of hand and foot.
Caulis Spatholobi: bitter, sweet, temperature.Return liver, kidney channel.Enrich blood, invigorate blood circulation, collateral dredging.Be used for menoxenia, blood deficiency and yellow complexion, paralysis and numbness, rheumatic arthralgia.
Radix Clematidis: hot, salty, temperature.Return urinary bladder channel.Expelling wind and removing dampness, removing obstruction in the collateral to relieve pain.Be used for rheumatic arthralgia, numb limbs and tense tendons, the contracture of muscle arteries and veins, joint stuffiness, the bone larynx of choking with sobs.
Medicine of the present invention has analgesia, antiinflammatory, blood circulation promoting and blood stasis dispelling, treatment and effectively prevents the effect of osteoarthritis.
Below further specify the beneficial effect of medicine of the present invention by the pharmacodynamics test of medicine of the present invention.
1, to mice because of turning round the influence of body number of times due to the acetic acid
Medicine of the present invention is little, in, heavy dose of (6.25,12.5,25.0g crude drug/kg, be equivalent to 5,10,20 times of clinical consumption respectively) irritate stomach and give mice after 7 days, the body number of times of turning round that can obviously resist because of 0.6% acetic acid induced mice increases, credit is analysed by statistics, in the medicine of the present invention, heavy dose of comparing with the normal saline group have remarkable meaning, is respectively P＜0.05 and P＜0.05.
2, to the influence of mice because of pain threshold due to the hot plate
Medicine of the present invention is little, in, heavy dose of (6.25,12.5,25.0g crude drug/kg, be equivalent to 5,10,20 times of clinical consumption respectively) irritate stomach and give mice after 7 days, can obviously improve pain threshold because of the hot plate induced mice, credit is analysed by statistics, the pain threshold of mice is compared with the normal saline group and is had remarkable meaning when 30 minutes and 60 minutes after administration, is respectively P＜0.05 ~ P＜0.001.
Test 1,2 promptings medicine of the present invention has certain analgesic activity.
3, to the influence of mice because of auricle swelling degree due to the dimethylbenzene
After Mice Auricle gives dimethylbenzene, can cause the auricle edema inflammatory model.Give medicine of the present invention little, in, heavy dose of (6.25,12.5,25.0g crude drug/kg, be equivalent to 5,10,20 times of clinical consumption respectively) 7 days, the swelling degree reduces, in the medicine wherein of the present invention, heavy dose of group compares with the normal saline group, significance, P＜0.05 and P＜0.05 points out medicine of the present invention can alleviate dimethylbenzene induced mice ease auricle swelling degree.
4, to the bullate influence of rat granuloma
Medicine of the present invention is little, in, heavy dose of (3.13,6.25,12.5g crude drug/kg, be equivalent to 2.5,5,10 times of clinical consumption respectively) can obviously suppress the bullate growth of rat granuloma, compare with the normal saline group, the highly significant meaning is arranged, medicine wherein of the present invention is little, in, heavy dose of group is respectively P＜0.05, P＜0.05 and P＜0.01 by statistics.
5, to the influence of rat because of paw swelling due to the carrageenin
Medicine of the present invention is little, in, heavy dose of (3.13,6.25,12.5g crude drug/kg, be equivalent to 2.5,5,10 times of clinical consumption respectively) can obviously suppress rat because of paw swelling due to the carrageenin, compare with the normal saline group, the highly significant meaning is arranged, in the medicine wherein of the present invention, heavy dose of group is respectively P＜0.05 ~ P＜0.001 by statistics.
Test 3,4,5 promptings medicine of the present invention has certain antiinflammatory action.
6, to the influence of experimental rabbit osteoarthritis model chondroproteoglycan content
Can cause the degraded of cartilage and the rapid disappearance of Dan Baijutang behind the rabbit intraarticular injection chymopapain, chondroproteoglycan content reduces after testing, and model group has been compared the highly significant meaning with blank, analyzes by statistics to be P＜0.01.Give medicine of the present invention little, in, heavy dose of (2.0,4.0,8.0g crude drug/kg, be equivalent to 1.6,3.2,6.4 times of clinical consumption respectively) after the treatment, in the medicine of the present invention, heavy dose of (4.0,8.0g crude drug/kg, be equivalent to 3.2,6.4 times of clinical consumption) after the modeling 7 days again after the treatment, Dan Baijutang content increases, and analysis is compared with model group and is respectively P＜0.01 by statistics; Chemoprophylaxis group of the present invention is analyzed by statistics and is compared variant with model group but P＞0.05.Result of the test shows that medicine of the present invention can resist the disappearance because of Dan Baijutang content in the inductive osteoarthritis model of the chymopapain rabbit cartilage.
7, to the histological influence of experimental rabbit osteoarthritis model cartilage pathology
Can cause the degraded of cartilage and the rapid disappearance of Dan Baijutang behind the rabbit intraarticular injection chymopapain, give to have some improvement after the Drug therapy of the present invention.Through rank test, medication therapy groups of the present invention as a result (4.0, (4.0g crude drug/kg) and model group relatively, there were significant differences (P＜0.05) for 8.0g crude drug/kg) and prevention group.Medication therapy groups of the present invention (4.0,8.0g crude drug/kg) has the obvious treatment effect to experimental rabbit osteoarthritis model cartilage pathology Histological change; (the cartilage histopathology that 4.0g crude drug/kg) can obviously alleviate experimental rabbit osteoarthritis model changes the prevention group, plays preventive effect.
Test 6,7 promptings medicine of the present invention can resist the disappearance because of Dan Baijutang content in the inductive osteoarthritis model of the chymopapain rabbit cartilage, and its osteoarthritis model histopathology is changed certain treatment and preventive effect.
8, to the influence of blood stasis model rat packed cell volume, plasma viscosity, whole blood viscosity
Rat causes whole blood viscosity and plasma viscosity to raise after giving adrenalin hydrochloride and frozen water and handling, and model group whole blood viscosity and the plasma viscosity value highly significant meaning of having compared with the normal saline group is respectively P＜0.001 and P＜0.001; Model group packed cell volume value increases, and the highly significant meaning of having compared with the normal saline group is P＜0.001, illustrates to adopt the method to cause the stasis syndrome model.After giving medicine of the present invention, animal erythrocyte hematocrit value reduces, and in the medicine wherein of the present invention, heavy dose of group packed cell volume value compares with model group, significance is respectively P＜0.01 and P＜0.01; Animal's whole blood viscosity and plasma viscosity value reduce, and in the medicine wherein of the present invention, the high shear rate value of heavy dose of group whole blood viscosity compares with model group, significance is respectively P＜0.05 and P＜0.05; In the medicine of the present invention, heavy dose of group whole blood viscosity low shear rate value compares with model group, significance is respectively P＜0.01 and P＜0.05; In the medicine of the present invention, heavy dose of group plasma viscosity value compares with model group, significance is respectively P＜0.01 and P＜0.05.
Test 8 promptings medicine of the present invention can reduce the blood viscosity of blood stasis model rat, has certain function of promoting blood circulation to disperse blood clots.
The specific embodiment:
Embodiment 1:
Each ingredient is pressed the row weight portion and is carried out proportioning:
6 parts of Rhizoma Drynariae, 5 parts of Radix Cyathulaes, 5 parts of Radix Angelicae Pubescentiss, 8 parts of Herba Taxillis, 10 parts of Radix Codonopsis, 5 parts of Radix Angelicae Sinensis, 2.5 parts in Nidus Vespae, 6 parts of Caulis Spatholobis, 4 parts of Radix Clematidis.The prescription of this proportioning lighter early stage patient of the state of an illness that suits.
Concrete preparation process is as follows:
Take by weighing Rhizoma Drynariae, Radix Angelicae Pubescentis by said ratio, with 10 times of amount 60% alcohol reflux three times, each 1 hour, merge extractive liquid, filtered, the alcohol extraction filtrate for later use;
Take by weighing Radix Cyathulae by said ratio, Herba Taxilli, Radix Codonopsis, Radix Angelicae Sinensis, Nidus Vespae, Caulis Spatholobi, Radix Clematidis adds 8 times of water gagings and decocts each 3 hours three times, collecting decoction filters, and filtrate is concentrated into the clear paste that relative density is 1.10 (70 ℃ of heat are surveyed), put coldly, add ethanol and make and contain alcohol amount and reach 70%, stir evenly, left standstill 24 hours, and inclined and get supernatant, filter, filtrate and above-mentioned alcohol extraction filtrate merge, and reclaim ethanol, and being concentrated into relative density is the thick paste of 1.30 (80 ℃ of heat are surveyed), add pharmaceutic adjuvant, comprise soluble starch and steviosin, drying is ground into fine powder, mixing, it is an amount of to add ethanol, makes granule, 60 ℃ of oven dry, granulate, pack promptly.
Embodiment 2:
Each ingredient is pressed the row weight portion and is carried out proportioning:
12 parts of Rhizoma Drynariae, 9 parts of Radix Cyathulaes, 9 parts of Radix Angelicae Pubescentiss, 15 parts of Herba Taxillis, 20 parts of Radix Codonopsis, 10 parts of Radix Angelicae Sinensis, 5 parts in Nidus Vespae, 12 parts of Caulis Spatholobis, 8 parts of Radix Clematidis.
Long or the heavier patient of symptom of the suitable course of disease of the prescription of this proportioning.
Concrete preparation method is with embodiment 1.
Claims (4)
1, the medicine of treatment osteoarthritis is characterized in that being made by following bulk drugs: Rhizoma Drynariae 6-12 part, Radix Cyathulae 5-9 part, Radix Angelicae Pubescentis 5-9 part, Herba Taxilli 8-15 part, Radix Codonopsis 10-20 part, Radix Angelicae Sinensis 5-10 part, Nidus Vespae 2.5-5 part, Caulis Spatholobi 6-12 part, Radix Clematidis 4-8 part.
2, the medicine of treatment osteoarthritis according to claim 1 is characterized in that the consumption of described each raw material medicaments in part by weight is: 6 parts of Rhizoma Drynariae, 5 parts of Radix Cyathulaes, 5 parts of Radix Angelicae Pubescentiss, 8 parts of Herba Taxillis, 10 parts of Radix Codonopsis, 5 parts of Radix Angelicae Sinensis, 2.5 parts in Nidus Vespae, 6 parts of Caulis Spatholobis, 4 parts of Radix Clematidis.
3, the medicine of treatment osteoarthritis according to claim 1 is characterized in that the consumption of described each raw material medicaments in part by weight is: 12 parts of Rhizoma Drynariae, 9 parts of Radix Cyathulaes, 9 parts of Radix Angelicae Pubescentiss, 15 parts of Herba Taxillis, 20 parts of Radix Codonopsis, 10 parts of Radix Angelicae Sinensis, 5 parts in Nidus Vespae, 12 parts of Caulis Spatholobis, 8 parts of Radix Clematidis.
4, the preparation method of the described medicine of a kind of claim 1 is characterized in that being undertaken by following process:
By proportioning get Rhizoma Drynariae, Radix Angelicae Pubescentis adds alcohol reflux, extracting solution filters, the alcohol extraction filtrate for later use;
Get Radix Cyathulae, Herba Taxilli, Radix Codonopsis, Radix Angelicae Sinensis, Nidus Vespae, Caulis Spatholobi, Radix Clematidis by proportioning, decoct with water, decocting liquid filters, and filtrate simmer down to clear paste, clear paste are put and added ethanol after cold and make and contain the alcohol amount and reach 60-70%, stir evenly, and leave standstill, and filter; Filtrate and above-mentioned alcohol extraction filtrate merge, and reclaim ethanol, are concentrated into thick paste, add adjuvant, and drying is pulverized, and mixing is granulated, oven dry, and granulate is promptly.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100955653A CN1326535C (en) | 2005-11-24 | 2005-11-24 | Medicine for treating bong arthritis and its preparing method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100955653A CN1326535C (en) | 2005-11-24 | 2005-11-24 | Medicine for treating bong arthritis and its preparing method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1813938A CN1813938A (en) | 2006-08-09 |
| CN1326535C true CN1326535C (en) | 2007-07-18 |
Family
ID=36906370
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100955653A Expired - Fee Related CN1326535C (en) | 2005-11-24 | 2005-11-24 | Medicine for treating bong arthritis and its preparing method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1326535C (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103191212A (en) * | 2013-03-26 | 2013-07-10 | 鲁道宗 | Externally used traditional Chinese medicine powder for treating osteoarthritis and preparation method thereof |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102258575B (en) * | 2010-03-19 | 2013-08-14 | 卢允良 | Plaster for treating scapulohumeral periarthritis and its preparation method |
| CN103251852B (en) * | 2013-05-28 | 2016-01-13 | 陈金宗 | A kind of medicine coordinating super micro knife to treat osteoarthritis |
| CN103330927B (en) * | 2013-07-04 | 2014-04-02 | 虞攀峰 | Drug for treatment of osteoarthritis |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1400007A (en) * | 2002-06-10 | 2003-03-05 | 郭好建 | Oral Chinese medicine for curing osteoarthropathy |
| CN1490017A (en) * | 2002-10-14 | 2004-04-21 | 何廷银 | Medicines against rheunatoid and rheumatic diseases |
-
2005
- 2005-11-24 CN CNB2005100955653A patent/CN1326535C/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1400007A (en) * | 2002-06-10 | 2003-03-05 | 郭好建 | Oral Chinese medicine for curing osteoarthropathy |
| CN1490017A (en) * | 2002-10-14 | 2004-04-21 | 何廷银 | Medicines against rheunatoid and rheumatic diseases |
Non-Patent Citations (3)
| Title |
|---|
| 中医辨证内治骨关节炎的研究 闵文等，中国中医骨伤科杂志，第11卷第2期 2003 * |
| 活血化瘀法在骨科的临床应用新进展 赖祥林，中国中医骨伤科杂志，第13卷第2期 2005 * |
| 活血化瘀法在骨科的临床应用新进展 赖祥林，中国中医骨伤科杂志，第13卷第2期 2005;中医辨证内治骨关节炎的研究 闵文等，中国中医骨伤科杂志，第11卷第2期 2003 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103191212A (en) * | 2013-03-26 | 2013-07-10 | 鲁道宗 | Externally used traditional Chinese medicine powder for treating osteoarthritis and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1813938A (en) | 2006-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1326535C (en) | Medicine for treating bong arthritis and its preparing method | |
| CN1286502C (en) | Medicine for treating gout affection and its symptoms | |
| WO2022237842A1 (en) | Pharmaceutical composition for treating rheumatoid arthritis and preparation method therefor | |
| CN103638231B (en) | Medicament for treating urticaria and preparation method of medicine | |
| CN103041262B (en) | Traditional Chinese medicine enema for curing chronic prostatitis and preparing method thereof | |
| CN102895610A (en) | Medicine for treating edema | |
| CN102743586A (en) | Medicine for treating kidney stone and gall-stone | |
| CN1298376C (en) | Pure Chinese medicine capsule for treating psora and its preparation technology | |
| CN103977106A (en) | Traditional Chinese medicine preparation for treating nephrotic syndrome and preparation method thereof | |
| CN110368445B (en) | Traditional Chinese medicine composition for treating psoriasis as well as preparation method and application thereof | |
| CN103536855A (en) | Traditional Chinese medicinal prescription for treating kidney stones and preparation method thereof | |
| CN103223078A (en) | Traditional Chinese medicine used for treating knee osteoarthritis through iontophoresis | |
| CN103028084A (en) | Traditional Chinese medicine composition for treating rheumatoid arthritis and preparation method | |
| CN102836342A (en) | Traditional Chinese medicine for treatment of hemorrhoid | |
| CN103386101B (en) | Traditional Chinese medicine preparation for nonspecific cystitis treatment and preparation method thereof | |
| CN110478416A (en) | The composition and its preparation method and application for treating rheumatic rheumatoid arthritis | |
| CN105031310A (en) | Medicine for treating wind-cold-dampness arthralgia and preparation method thereof | |
| CN102846750B (en) | Fengtongning composite preparation and preparation method thereof | |
| CN103638448B (en) | Medicine used for treating rheumatoid arthritis, and preparation method thereof | |
| CN103845583B (en) | A kind of Chinese medicine preparation and preparation method for the treatment of chronic hepatitis | |
| CN1381250A (en) | Chinese medicine 'lidandishi' for treating hepatobiliary calculus and cholecystitis | |
| CN102626479B (en) | External-use Chinese herbal medicine composition for chronic rheumatism treatment | |
| CN110215474B (en) | Traditional Chinese medicine composition for promoting blood circulation to remove blood stasis and application thereof | |
| CN109893557B (en) | Traditional Chinese medicine composition for treating sequelae of pelvic inflammatory disease | |
| CN107375809A (en) | A kind of Chinese medicine for treating constipation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Shanghai Rosant Wuhu Pharmaceutical Co., Ltd. Assignor: Anhui Jiuding Pharmaceutical Technology Co., Ltd. Contract record no.: 2010340000068 Denomination of invention: Medicine for treating bong arthritis and its preparing method Granted publication date: 20070718 License type: Exclusive License Open date: 20060809 Record date: 20100427 |
|
| ASS | Succession or assignment of patent right |
Owner name: SHANGHAI YUESHENG WUHU PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: ANHUI JIUDING PHARMACEUTICAL SCI. + TECH. CO., LTD. Effective date: 20110901 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 230022 HEFEI, ANHUI PROVINCE TO: 241000 WUHU, ANHUI PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20110901 Address after: 241000 Anhui province Wuhu City Jiuhua Road No. 120 Wuhu biological pharmaceutical science and Technology Park Patentee after: Shanghai Rosant Wuhu Pharmaceutical Co., Ltd. Address before: 230022 scientific research office building, intersection of Mount Huangshan road and Susong Road, Anhui, Hefei Patentee before: Anhui Jiuding Pharmaceutical Technology Co., Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070718 Termination date: 20181124 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |